Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076595 | 1.00 | L3MBTL1 (0.39) | L3MBTL1GRM1ACACBKDM4EHSD17B10 | |
| SCHEMBL1076814 | 0.82 | L3MBTL1 (0.39) | L3MBTL1GRM1ACACBACACAACE2 | |
| SCHEMBL1076815 | 0.82 | L3MBTL1 (0.39) | L3MBTL1GRM1ACACBACACAACE2 | |
| SCHEMBL2502182 | 0.79 | GRM1 (0.42) | GRM1KDM4ERAB9AACE2ALDH1A1 | |
| SCHEMBL20768594 | 0.75 | GRM1 (0.43) | GRM1KDM4ERAB9ANPC1ACE2 | |
| SCHEMBL23113901 | 0.72 | HTT (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL2496346 | 0.71 | CYP1A2 (0.41) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6558052 | 0.71 | KMT2A (0.50) | L3MBTL1GRM1ACACBACE2ALDH1A1 | |
| SCHEMBL6558054 | 0.71 | KMT2A (0.50) | L3MBTL1GRM1ACACBACE2ALDH1A1 | |
| SCHEMBL30202757 | 0.70 | GPR139 (0.47) | L3MBTL1ACACBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | L3MBTL1 4508/4885GRM1 1136/4885ACACB 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.